Last reviewed · How we verify
Lartruvo (OLARATUMAB)
Lartruvo (Olaratumab) is a small molecule drug developed by Eli Lilly and Co, targeting the platelet-derived growth factor receptor alpha. It works as a receptor antagonist to inhibit tumor growth. Lartruvo is FDA-approved for the treatment of soft tissue sarcoma. The commercial status of Lartruvo is patented, and it is still owned by Eli Lilly and Co. Key safety considerations include potential severe side effects such as neutropenia and thrombocytopenia.
At a glance
| Generic name | OLARATUMAB |
|---|---|
| Sponsor | Eli Lilly |
| Drug class | Platelet-derived Growth Factor Receptor alpha Antagonist |
| Target | Platelet-derived growth factor receptor alpha |
| Modality | Monoclonal antibody |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 2016 |
Approved indications
- Sarcoma of soft tissue
Common side effects
Key clinical trials
- A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma (PHASE3)
- 89Zr-olaratumab Dosimetry in Participants With Soft Tissue Sarcoma (PHASE1)
- Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma
- A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma (PHASE1)
- Olaratumab Plus Trabectedin in Advanced Soft-tissue Sarcoma Patients Soft-tissue Sarcoma Patients (PHASE1)
- A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer (PHASE1,PHASE2)
- A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma (PHASE1,PHASE2)
- Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma (PHASE1)
Patents
| Patent | Expiry | Type |
|---|---|---|
| Biologic Exclusivity |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lartruvo CI brief — competitive landscape report
- Lartruvo updates RSS · CI watch RSS
- Eli Lilly portfolio CI